Research Analysts Offer Predictions for FULC Q3 Earnings

Posted by Stanley Muller on Jun 4th, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report issued on Tuesday, June 2nd. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.27). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.65) EPS, FY2027 earnings at ($0.13) EPS and FY2028 earnings at ($0.13) EPS.

A number of other equities research analysts also recently weighed in on FULC. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 target price for the company. in a report on Tuesday. Citigroup downgraded Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a report on Tuesday. Jefferies Financial Group set a $4.00 target price on Fulcrum Therapeutics in a report on Tuesday. Cantor Fitzgerald downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, Leerink Partners downgraded Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price for the company. in a report on Tuesday. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $8.20.

Get Our Latest Stock Analysis on FULC

Fulcrum Therapeutics Stock Performance

FULC opened at $3.22 on Thursday. Fulcrum Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $15.74. The company has a market capitalization of $214.55 million, a P/E ratio of -2.80 and a beta of 2.93. The stock has a fifty day moving average of $7.08 and a 200-day moving average of $9.14.

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last announced its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Aberdeen Group plc increased its position in shares of Fulcrum Therapeutics by 135.0% in the third quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock worth $1,269,000 after purchasing an additional 79,265 shares during the period. Braidwell LP bought a new position in shares of Fulcrum Therapeutics in the third quarter worth $2,019,000. Boothbay Fund Management LLC increased its position in shares of Fulcrum Therapeutics by 104.2% in the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock worth $6,241,000 after purchasing an additional 346,136 shares during the period. Suvretta Capital Management LLC increased its position in shares of Fulcrum Therapeutics by 5.9% in the third quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock worth $49,505,000 after purchasing an additional 298,100 shares during the period. Finally, GSA Capital Partners LLP increased its position in shares of Fulcrum Therapeutics by 256.4% in the third quarter. GSA Capital Partners LLP now owns 116,068 shares of the company’s stock worth $1,068,000 after purchasing an additional 83,505 shares during the period. Institutional investors own 89.83% of the company’s stock.

Key Headlines Impacting Fulcrum Therapeutics

Here are the key news stories impacting Fulcrum Therapeutics this week:

Negative Sentiment: Fulcrum discontinued pociredir after FDA safety concerns, effectively removing its only clinical-stage asset and sharply weakening the company’s near-term outlook. Reuters article
Negative Sentiment: Multiple brokerages downgraded the stock, including Cantor Fitzgerald, Leerink Partners, Stifel, HC Wainwright, and JPMorgan, reflecting reduced confidence after the program shutdown.
Negative Sentiment: Several law firms and shareholder groups announced investigations into possible securities-law violations, adding litigation risk and more uncertainty for investors. PR Newswire article
Neutral Sentiment: The company is exploring strategic alternatives, including a potential sale or merger, which could provide a catalyst if value can be salvaged from the remaining assets. Yahoo Finance article

About Fulcrum Therapeutics

(Get Free Report)

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.